Thursday, October 06, 2016 9:17:21 PM
Synthetic Biologics produces therapies for infectious diseases that still protect the natural microbial balance in the gastrointestinal tract. One of its drugs in development is ribaxamase, code-named SYN-004, designed to prevent infections from Clostridium difficile or C. difficile bacteria. According to CDC, almost a half-million C. difficile infections occurred in the U.S. in 2011, leading to 29,000 deaths within 30 days of diagnosis.
C. difficile infections are often contracted in health care facilities, such as clinics and hospitals, causing inflammation in the colon, and symptoms including watery diarrhea, abdominal pain, nausea, loss of appetite, and fever. People who have other illnesses or conditions requiring prolonged use of antibiotics, and the elderly, are at greater risk of this disease.
SYN-004 is a synthetic enzyme formulated as an oral drug to degrade a common type of antibiotics, known as beta-lactam antibiotics, in the gastrointestinal tract. Beta-lactam antibiotics include widely used penicillins and cephalosporins, administered through intravenous infusions, which can pass into the gastrointestinal tract and kill helpful microbes, such as those that naturally protect against C. difficile infections. By degrading beta-lactam antibiotics, SYN-004 protects helpful microbes, thus preserving the body’s natural defenses against C. difficile.
The CDC grant funds a study by Synthetic Biologics to assess the way pressure from intravenous antibiotics encourages the emergence of antibiotic resistance in gut microbial communities. The company plans to extract DNA samples from participants enrolled in an intermediate-stage clinical trial testing SYN-004 against a placebo to prevent C. difficile infections. The trial is enrolling patients receiving ceftriaxone, a type of beta-lactam antibiotic, administered intravenously, for lower respiratory infections. The study team will look for changes in the presence and number of genes associated with antibiotic resistance in those DNA samples.
Synthetic Biologics is the only grant recipient from industry in the initiative, with the other investigators coming from universities and OpenBiome, a not-for-profit organization. OpenBiome operates a stool bank that collects fecal samples for research and transplants, a treatment option for C. difficile infections.
Recent TOVX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:10:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:07:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:01:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:00:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:15:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2023 11:10:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 10:05:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 10:06:35 AM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 08/16/2023 09:24:26 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/15/2023 01:53:41 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/14/2023 09:11:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 08:30:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 01:03:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 12:10:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2023 01:22:02 PM
- Another Biotech Stealing The Premarket Spotlight • AllPennyStocks.com • 06/28/2023 02:15:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM